B+
Bull case
25%
Probability
Target price
$7.50
-41.9% vs current
SLS
SELLAS Life Sciences GroupDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-21
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$5.40
-58.1% vs current
B-
Bear case
30%
Probability
Target price
$2.80
-78.3% vs current
AI sentiment snapshot
Latest data as of 2026-04-15
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
0.0
Score
AI commentary
Primary-source evidence supports a cautious monitoring stance rather than a clean bullish call. The March 19, 2026 8-K press release shows real clinical and balance-sheet progress: REGAL is nearing its final event threshold, first patient dosing has occurred in the front-line SLS009 study, and cash plus post-year-end warrant proceeds materially improved runway [#8-K-2026-03-19][#10-K-2026-03-19]. But the deterministic score remains neutral with modest catalyst density, and most value still hinges on binary future clinical milestones rather than durable operating proof. Recent negative market chatter exists, but it is lower quality than the primary filings and does not by itself change the thesis.
RankAlpha Sentiment Codex - 2026-04-15
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-06-30eventEuropean SLS009 expansion begins enrolling through IMPACT-AML networkHigh impact
In the March 19, 2026 corporate update, SELLAS said its January 2026 IMPACT-AML collaboration is expected to enroll about 40 newly diagnosed AML patients in Europe during Q2 2026, giving investors a concrete execution checkpoint for SLS009 beyond the U.S. program [#8-K-2026-03-19].
2026-08-31eventREGAL Phase 3 reaches 80-event final analysis and topline disclosureHigh impact
SELLAS said the pivotal Phase 3 REGAL AML study had recorded 72 events as of December 26, 2025, remains fully blinded, and will move to database lock, statistical analysis, unblinding, and topline disclosure after the pre-specified 80th event; the company also says a positive outcome could support a BLA path for GPS [#8-K-2026-03-19][#10-K-2026-03-19].
2026-09-30catalystFront-line SLS009 AML study enrollment builds after first patient dosingHigh impact
SELLAS reported first patient dosing in its randomized 80-patient first-line AML Phase 2 study and the 10-K says enrollment began in Q1 2026 after FDA feedback following positive r/r AML Phase 2 results; steady enrollment and any clean efficacy/safety updates would strengthen the second value driver behind GPS, but this remains earlier-stage than REGAL [#8-K-2026-03-19][#10-K-2026-03-19].
Recommendation
N/A
No formal recommendation provided.
As of 2026-04-15 • Updated nightlySource: Internal modelMethodology